Abstract
Enalapril maleate, an angiotensin Converting Enzyme Inhibitor (CEI), is an effective antihypertensive agent. It lowers peripheral and Renal Vascular Resistances (RVR), increases Renal Plasma Flow (RPF) and Blood Flow (RBF), whereas Glomerular Filtration Rate (GFR) is usually unchanged. Since Angiotensin II (AII) alters renal hemodynamics by increasing efferent arteriolar resistance, reduces GFR by decreasing ultrafiltration coefficient (LpA), the product of the glomerular capillary wall hydraulic conductivity (Lp) and the effective capillary surface area available for filtration (A), and produces proteinuria, CEI may have the potentiality to correct intraglomerular hypertension, to normalize GFR and to decrease proteinuria.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
BRADFORD, M.M. Anal. Biochem. 72: 218–221, 1976.
COLE, B.R. et al. N. Engl. J. Med. 287: 1109–1114, 1972.
BLAUFOX, M.D. et al. Nephron 3:274–281, 1966.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Academic Publishers
About this chapter
Cite this chapter
Grazi, G. et al. (1989). ACE Inhibition and Progression of Renal Injury in Man. In: Andreucci, V.E., Dal Canton, A. (eds) Current Therapy in Nephrology. Developments in Nephrology, vol 24. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0865-2_46
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0865-2_46
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8209-9
Online ISBN: 978-1-4613-0865-2
eBook Packages: Springer Book Archive